Intra-Cellular Therapies
ITCI
$72.37
Share price
0.51%
Change (1 day)
15.26%
Change (1 year)
Categories
Operating Margin for Intra-Cellular Therapies (ITCI)
Operating Margin as of April 2024 (TTM): -50.58%
According to Intra-Cellular Therapies's latest financial reports and stock price the company's current Operating Margin is -50.58%. At the end of 2022 the company had an Operating Margin of -105.82%.
Operating Margin history for Intra-Cellular Therapies from 2014 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -105.82% | -69.74% |
| 2021 | -349.65% | -65.93% |
| 2020 | -1,026.28% | -99.6% |
| 2019 | -254,090.46% | |
| 2017 | -40,203.17% | 15.29% |
| 2016 | -34,872.43% | -69.89% |
| 2015 | -115,815.85% | 2079.09% |
| 2014 | -5,314.87% | 454.43% |
| 2013 | -958.61% | 82.65% |
| 2012 | -524.84% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | -141.63% | 180.01% | 🇺🇸 USA |
 MediciNova MNOV | -250.93% | 396.11% | 🇺🇸 USA |
 Curis CRIS | -426.66% | 743.53% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.